Clinical trials: Choroidal Diseases
Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
This phase II trial studies the effect of transarterial chemoembolization in treating patients with uveal melanoma that has spread to the liver (liver metastases).
- Conditions
- Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8
- Trial name
- NCT04728633
- Testing
- Carmustine, Ethiodized Oil, Transarterial Chemoembolization
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Thomas Jefferson University
Choroideremia
THOR - Tübingen Choroideremia Gene Therapy Trial
An open label monocentric phase II trial in adult males with a clinical phenotype of choroideremia and a confirmed molecular diagnosis of a null mutation in the gene encoding REP1 to assess the anatomical and functional outcomes…
- Trial name
- THOR (NCT02671539)
- Testing
- rAAV2.REP1
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- STZ eyetrial
Choroid Diseases
Choroid In Coronary Artery Disease
Purpose: To investigate any relationship between choroid thickness (CTh) and coronary artery disease (CAD), particularly in its earlier stages before clinically evident.
- Trial name
- NCT06442176
- Testing
- OCT
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Bursa Yuksek Ihtisas Training and Research Hospital
Age-related Macular Degeneration, Choroidal Neovascularization
Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD
This study was designed to evaluate the efficacy and safety of two different regimens of 0.5 mg ranibizumab given as intravitreal injection in patients with neovascular age-related macular degeneration
- Trial name
- TREND (NCT01948830)
- Testing
- Ranibizumab 0.5mg
- Where
- 91 sites in Belgium, Chile and 17 more
- Volunteers
- 650 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration, Choroidal Neovascularization
Imaging of the Angiofibrotic Switch in Neovascular AMD
The content of this research project is to identify the angiofibrotic switch, the transition from angiogenesis to fibrosis, in neovascular age-related macular degeneration (nAMD) longitudinally.
- Trial name
- NCT03838679
- Testing
- Best-corrected Visual acuity testing (BCVA), Optical coherence tomography (OCT), Color fundus photography (CFP)
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Medical University of Vienna
Photobiomodulation, Age-Related Macular Degeneration
Photobiomodulation for Dry Age Related Macula Degeneration
The study will investigate the effect of photobiomodulation treatment on the risk of developing late age related macula degeneration (AMD) in the study eye in patients with wet AMD in the fellow eye.
- Trial name
- NCT05507840
- Testing
- Valeda machine
- Volunteers
- 121 people
- Sponsor
- Oslo University Hospital
Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
This study compared the effect of ranibizumab administered as monotherapy versus ranibizumab administered in combination with verteporfin photodynamic therapy (PDT) on visual acuity in patients with symptomatic macular polypoidal…
- Trial name
- EVEREST II (NCT01846273)
- Testing
- Ranibizumab, Verteporfin PDT
- Where
- 41 sites in Hong Kong, Japan and 5 more
- Volunteers
- 321 people
- Sponsor
- Novartis Pharmaceuticals
Wet Macular Degeneration
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in…
- Trial name
- DAZZLE (NCT04049266)
- Testing
- KSI-301, Aflibercept
- Where
- 75 sites in United States, Czechia and 5 more
- Volunteers
- 559 people
- Sponsor
- Kodiak Sciences Inc
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Polypoidal Choroidal Vasculopathy
Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation
To evaluate the efficacy and safety of intravitreal aflibercept injection in the treatment of PCV
- Trial name
- EPIC (NCT01871376)
- Testing
- Intravitreal aflibercept injection 2.0mg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Gregg T. Kokame, MD
Beta-Thalassemia
Choroidal Thickness in Beta-thalassemia Patients
The purpose of this study is to examine choroidal thickness in beta-thalassemia patients and compare it to the one of healthy controls.
- Trial name
- NCT04067258
- Testing
- EDI-OCT
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital of Patras
Choroidal Neovascularization
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
This multiple-center, multiple-dose and regimen, randomized, double-masked active comparator-controlled, double-masked, five parallel group, 36-week study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of…
- Trial name
- AVENUE (NCT02484690)
- Testing
- Faricimab, Ranibizumab
- Where
- 52 sites in United States
- Volunteers
- 273 people
- Sponsor
- Hoffmann-La Roche
Birdshot Chorioretinopathy, Cystoid Macular Edema
Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a
Birdshot Retine choroidopathy (BRC) is a sight threatening posterior uveitis. The long term visual outcome has recently be studied showing a legal blindness to 14% at 5 years.
- Conditions
- Birdshot Chorioretinopathy, Cystoid Macular Edema, Transient Partial Visual Loss
- Trial name
- BIRDFERON (NCT00508040)
- Testing
- interferon alpha 2a, prednisone
- Where
- France
- Volunteers
- 58 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Choroidal Neovascularization
TTT Versus PDT for Treatment of Choroidal Neovascularization in Age-Related Macular Degeneration
The purpose of the study is to compare photodynamic therapy to transpupillary thermotherapy as a treatment method for choroidal neovascularization in age-related macular degeneration ( AMD).
- Trial name
- NCT00260403
- Testing
- Photodynamic therapy versus Transpupillary thermotherapy
- Where
- Sweden
- Volunteers
- 140 people
- Sponsor
- St. Erik Eye Hospital
Melanoma
Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas
Ocular melanomas have been treated for a long time by enucleation, with an unfavorable major impact on the patient's quality of life, social life, self-image, how they feel about others and about living with this disability.
- Trial name
- HYGROMEL (NCT02602756)
- Testing
- Protontherapy
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Centre Antoine Lacassagne
Choroideremia
A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111
The objective of the study is to evaluate the safety of bilateral, sequential sub-retinal administration of a single dose of BIIB111 in adult male participants with Choroideremia (CHM).
- Trial name
- GEMINI (NCT03507686)
- Testing
- BIIB111
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 66 people
- Sponsor
- Biogen
Age Related Macular Degeneration
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
The purpose of the study is to evaluate the relative efficacy and safety of treatment of neovascular AMD with Lucentis on a fixed schedule, Avastin on a fixed schedule, Lucentis on a variable schedule, and Avastin on a variable…
- Trial name
- NCT00593450
- Testing
- ranibizumab, bevacizumab
- Where
- 59 sites in United States
- Volunteers
- 1,208 people
- Sponsor
- University of Pennsylvania
Age Related Macular Degeneration
PHP Home Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization (CNV)
The primary objective of this study is to assess the ability of the PHP \& HPHP to detect newly diagnosed non treated Chorodial neovascularization (CNV) lesion associate with advanced age related Macular Degeneration (AMD) and…
- Trial name
- NCT00359008
- Where
- Israel
- Volunteers
- 336 people
- Sponsor
- Notal Vision Ltd.
Choroidal Neovascularization, Age-related Macular Degeneration
Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared…
- Trial name
- EMERGE (NCT02358889)
- Testing
- hI-con1, ranibizumab
- Where
- 48 sites in United States
- Volunteers
- 88 people
- Sponsor
- Iconic Therapeutics, Inc.
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT03834753
- Testing
- bevacizumab, ranibizumab
- Where
- 50 sites in United States
- Volunteers
- 228 people
- Sponsor
- Outlook Therapeutics, Inc.